Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00360438
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2012-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00354887
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00354523
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00354705
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00354978
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 135
- Registration Number
- NCT00352846
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00353015
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Experience of Brain Tumor Caregivers
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00352820
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Experience of Having Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 187
- Registration Number
- NCT00353106
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide for Patients With Myelofibrosis (MF)
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00352794
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States